HAZLET, N.J. - s4story -- In this program, experts will discuss the risk factors for, and risks of hyperkalemia, treatment goals of  acute and chronic hyperkalemia, the importance of RAASi in CKD and HF patients, the potential adverse outcomes in individuals with ESRD undergoing adequate hemodialysis with predialysis hyperkalemia,  and evidence with K+ binders in various patient populations. A multi-specialty faculty, consisting of two nephrologists, a dietician, and a primary care physician, will then discuss cardiorenal challenges faced by family physicians, including dietary recommendations to their patients with hyperkalemia. In addition, the panel will identify key cardiorenal messages for patients taking K+ binders (for hyperkalemia) and sodium-glucose cotransporter 2 (SGLT2) inhibitors which reduce the risk for hyperkalemia and significantly improve cardiorenal outcomes.

More on S For Story

• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)

Click here for more information

CHAIR

Csaba P. Kovesdy, MD
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clinical Trials Program in Nephrology
University of Tennessee Health Science Center
Memphis VA Medical Center
Memphis, Tennessee

FACULTY

Deborah Clegg, PhD
Vice President for Research
Texas Tech University Health Sciences Center El Paso
Professor of Internal Medicine
Paul L. Foster School of Medicine El Paso, Texas

Jay Shubrook, DO
Professor, Primary Care Department
Touro University California College of Osteopathic Medicine
Vallejo, California

Bruce Spinowitz, MD
Associate Director, Nephrology
Vice Chairman, Medicine
New York-Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York

This educational activity is intended for primary care physicians and other clinicians managing patients at risk for, and with hyperkalemia.

More on S For Story

• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
• Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
• The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
• $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
• SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%

Voxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certifi cate of completion as AANP accepts AMA PRA Category 1.5 Credits™ through its reciprocity agreements.

Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #AAFPFMX #hyperkalemia #physician #potassium #cardiorenal #diet